Here are four things to know.
1. Datum Orthobiologics is affiliated with Datum Biotech, whose proprietary Glymatrix technology has been used in over 500,000 clinical dental and aesthetic procedures. There are more than 110 scientific publications and several case studies about the technology.
2. The new company will initially focus on bone graft products, particularly for spine fusion and fracture grafts in trauma.
3. Gilad Karni was appointed CEO of the newly formed company.
4. Datum Orthobiologics is currently in a fundraising round.
More articles on biologics:
Siberian tiger receives stem cell treatment for joint pain — 3 insights
Texas Back Institute heads stem cell trial for rejuvenating spinal tissue— 5 notes
2-D nanoparticles can direct mesenchymal stem cells to become bone, cartilage — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
